Output details

Contrast agent-free sonoporation: the use of an ultrasonic standing wave microfluidic system for the delivery of pharmaceutical agents

Significance of output:

Transfection and drug delivery in-vitro are rapidly growing markets with transfection alone accounting for of over $100M annually and a much large potential for in-vivo applications. Sonoporation is one method of achieving this and while most of the work in this area has used microbubbles, this is the most systematic study to date showing that sonoporation can be successful, with high viability, in the absence of contrast-agent bubbles (which increase the potential for localised cell damage). This approach has potential for reducing early-stage animal experimentation and has already led to commercial interest and $50k of follow-up funding from Agilent (gerry_owen@agilent.com)